Reproxalap is an investigational drug candidate for the treatment of dry eye disease.

“In discussions with ophthalmologists and optometrists, nearly all say they would choose SLT first if it were their own eye. However, when asked how often their patients receive SLT as initial therapy, most report rates around 10%.” – John Berdahl, MD, Vance Thompson Vision

TECNIS PureSee IOL is the first and only US FDA‑approved extended depth of focus (EDOF) IOL with no warning on loss of contrast sensitivity

“The increased risk of NAION with Wegovy is due to the higher dosage of semaglutide…the difference between the two dosages and the rates of NAION may indicate a dose-dependent increase in risk.” – Benjamin Bert, MD

“These findings support the role of OCTA as an adjunctive tool for monitoring [hydroxychloroquine-induced] retinal changes, while further longitudinal studies are needed to clarify its predictive value.” – Study authors

The specialty treats a diverse patient population and the scientific discourse should reflect that breadth of experience and insight. Breaking these patterns requires intentional effort and sustained commitment.